Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers
Authors:
- 1 October 1993
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 53 (2) , 135-144
Abstract
The malignant potential of solid tumors is related to the ability to invade adjacent tissue and to metastasize. These properties of cancer cells depend on the synthesis of proteolytic enzymes which are able to digest adjacent connective tissue and basement membranes. We hypothesized that all elements of the plasminogen activation system might be overexpressed in malignant human breast tumors, functioning as an essential element in tumor invasion and metastasis. As determined by histopathological methods, the malignant tumors showed statistically significantly higher expression of urokinase plasminogen activator (uPA), type‐1 plasminogen activator inhibitor (PAI‐1), and especially urokinase plasminogen activator receptor (uPAR) than benign tissues. All those elements were present in higher amounts in the cancer cells than in the cells of benign or normal breast tissues. High exhibition of tissue plasminogen activator (tPA) found in cancer seems to be random and not related to the malignant or benign state, since benign and malignant tumors show overexpression of tissue plasminogen activator with similar frequency. When the tumors express high amounts of uPA, they express a high amount of uPAR in 50% of cases and PAI‐1 in 57.3% of cases. When urokinase is expressed in low amount, the receptor is low in 28.6% and inhibitor in 21.4% of malignant breast tumors. This statistically significant consensus, 78.6% in the case of urokinase and its receptor and 78.6% in case of urokinase and its inhibitor, suggests that these activities may be the result of a unique mechanism of control, activated in the last steps of malignant transformation.Keywords
This publication has 20 references indexed in Scilit:
- Regulation of urokinase plasminogen activator localization in keratinocytes by calcium ion and E-cadherinExperimental Cell Research, 1992
- Increase of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in plasma after thrombolytic therapy of patients with myocardial infarction. A randomised, placebo-controlled studyFibrinolysis, 1992
- Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancerFibrinolysis, 1990
- Plasminogen Activators in Human Prostate Cancer Cell Lines and Tumors: Correlation with the Aggressive PhenotypeJournal of Urology, 1989
- Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.Proceedings of the National Academy of Sciences, 1989
- Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.Proceedings of the National Academy of Sciences, 1989
- Surface receptors for urokinase plasminogen activatorFibrinolysis, 1988
- Effect of urokinase on the proliferation of primary cultures of human prostatic cellsThrombosis Research, 1987
- Identification and localization of urokinase‐type plasminogen activator in human NK‐cellsInternational Journal of Cancer, 1986
- Plasminogen Activators, Tissue Degradation, and Cancer1985